Search

Eflapegrastim

in which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer

Selexipag

circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

Fruquintinib

This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … Although [bevacizumab] is successful in sustaining target inhibition, mandatory intravenous dosing, immunogenicity, and the potential to induce autoimmune diseases hinder its clinical application.

Mirikizumab

[L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.

Leptin

Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

Calcium alginate

Phenyltoloxamine

It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.

Brensocatib

[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation.

Meningococcal polysaccharide vaccine group Y

It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

BNT162B2 Omicron (LP.8.1)

BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19. … [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.